234 related articles for article (PubMed ID: 946595)
1. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
LePage GA; Worth LS; Kimball AP
Cancer Res; 1976 Apr; 36(4):1481-5. PubMed ID: 946595
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
Cass CE; Au-Yeung TH
Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
Lee SH; Caron N; Kimball AP
Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
[TBL] [Abstract][Full Text] [Related]
4. Resistance to 9-beta-D-arabinofuranosyladenine in murine tumor cells.
LePage GA
Cancer Res; 1978 Aug; 38(8):2314-6. PubMed ID: 580902
[TBL] [Abstract][Full Text] [Related]
5. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
Caron N; Lee SH; Kimball AP
Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
White EL; Shaddix SC; Brockman RW; Bennett LL
Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
[TBL] [Abstract][Full Text] [Related]
7. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
Cass CE; Selner M; Phillips JR
Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
Cass CE; Tan TH; Selner M
Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Brockman RW; Cheng YC; Schabel FM; Montgomery JA
Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
[TBL] [Abstract][Full Text] [Related]
10. Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.
Kufe DW; Major PP; Munroe D; Egan M; Herrick D
Cancer Res; 1983 May; 43(5):2000-4. PubMed ID: 6831429
[TBL] [Abstract][Full Text] [Related]
11. Potentiation by 2'-deoxycoformycin of the inhibitory effect by 3'-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro.
Glazer RI; Lott TJ; Peale AL
Cancer Res; 1978 Aug; 38(8):2233-8. PubMed ID: 307428
[TBL] [Abstract][Full Text] [Related]
12. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
Suling WJ; Rice LS; Shannon WM
Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695
[No Abstract] [Full Text] [Related]
13. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
14. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
Plunkett W; Cohen SS
Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
[TBL] [Abstract][Full Text] [Related]
15. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
16. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
19. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA
Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
